Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities

[1]  B. Ganatra,et al.  In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments , 2023, Reproductive Health.

[2]  S. Budhathoki,et al.  Analysis of maternal and newborn training curricula and approaches to inform future trainings for routine care, basic and comprehensive emergency obstetric and newborn care in the low- and middle-income countries: Lessons from Ethiopia and Nepal , 2021, PloS one.

[3]  S. Meaney,et al.  Clinical practice guidelines for recurrent miscarriage in high-income countries: a systematic review. , 2021, Reproductive biomedicine online.

[4]  C. Kilfedder,et al.  A descriptive analysis of medical abortion commodity availability and pricing at retail outlets in 44 countries across four regions globally , 2021, Sexual and reproductive health matters.

[5]  E. Coast,et al.  The mesoeconomics of abortion: A scoping review and analysis of the economic effects of abortion on health systems , 2020, PloS one.

[6]  I. Cameron,et al.  Access to and sustainability of abortion services: a systematic review and meta-analysis for the National Institute of Health and Care Excellence-new clinical guidelines for England. , 2020, Human reproduction update.

[7]  A. Fatusi,et al.  Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria , 2020, BMJ Open.

[8]  F. Ofei,et al.  Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana. , 2019, Health policy and planning.

[9]  Samikshya Poudel,et al.  Factors associated with unsafe abortion practices in Nepal: Pooled analysis of the 2011 and 2016 Nepal Demographic and Health Surveys , 2019, PloS one.

[10]  S. Ghuman,et al.  Factors associated with unintended pregnancy among women attending a public health facility in KwaZulu-Natal, South Africa , 2018, South African Family Practice.

[11]  K. Keenan,et al.  Medical Abortion Provision by Pharmacies and Drug Sellers in Low‐ and Middle‐Income Countries: A Systematic Review , 2018, Studies in family planning.

[12]  B. Sarker,et al.  Provision of menstrual regulation with medication among pharmacies in three municipal districts of Bangladesh: a situation analysis. , 2017, Contraception.

[13]  Susheela Singh,et al.  Abortion Worldwide 2017: Uneven Progress and Unequal Access , 2018 .

[14]  Ich Q3DR.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS , 2018 .

[15]  L. Alkema,et al.  Global, regional, and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model , 2017, The Lancet.

[16]  A. Sorhaindo,et al.  Implementation considerations when expanding health worker roles to include safe abortion care: a five-country case study synthesis , 2017, BMC Public Health.

[17]  F. Ngabo,et al.  Making Abortion Safer in Rwanda: Operationalization of the Penal Code of 2012 to Expand Legal Exemptions and Challenges. , 2017, African journal of reproductive health.

[18]  F. Suleman,et al.  Selection of essential medicines for South Africa - an analysis of in-depth interviews with national essential medicines list committee members , 2017, BMC Health Services Research.

[19]  Phil Harvey.  Medical abortion: the hidden revolution , 2015, Journal of Family Planning and Reproductive Health Care.

[20]  C. Gerdts,et al.  An exploratory study of what happens to women who are denied abortions in Cape Town, South Africa , 2015, Reproductive Health.

[21]  E. Faxelid,et al.  Health care providers’ perceptions of and attitudes towards induced abortions in sub-Saharan Africa and Southeast Asia: a systematic literature review of qualitative and quantitative data , 2015, BMC Public Health.

[22]  P. Shrestha,et al.  Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion , 2014, Reproductive health matters.

[23]  S. Thapa,et al.  Women's knowledge of abortion law and availability of services in Nepal. , 2014, Journal of biosocial science.

[24]  K. Culwell,et al.  Addressing barriers to safe abortion , 2013, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  B. Winikoff,et al.  Use of medicines changing the face of abortion. , 2012, International perspectives on sexual and reproductive health.

[26]  L. Ashford,et al.  Making abortion services accessible in the wake of legal reforms. , 2012, Issues in brief.

[27]  F. Coeytaux,et al.  Assessing the global availability of misoprostol , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[28]  D. Nelson,et al.  Effective scale-up: avoiding the same old traps , 2009, Human resources for health.

[29]  L. Myer,et al.  Knowledge of the abortion legislation among South African women: a cross-sectional study , 2006, Reproductive health.

[30]  H. Rees,et al.  Why are women still aborting outside designated facilities in metropolitan South Africa? , 2005, BJOG : an international journal of obstetrics and gynaecology.

[31]  A. Koyama,et al.  Advanced practice clinicians' interest in providing medical abortion: results of a California survey. , 2005, Perspectives on sexual and reproductive health.

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..